Zulu
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Izigaba Zemikhiqizo
Imikhiqizo efakiwe
I-Innovative Gene Therapy Inikeza Ithemba Elisha Ngeziguli zeSickle Cell kanye ne-Thalassemia

I-Innovative Gene Therapy Inikeza Ithemba Elisha Ngeziguli zeSickle Cell kanye ne-Thalassemia
I-FUCASO: I-Revolutionary Fully-Human BCMA CAR-T Therapy Ngokusebenza Okungaqhathanisiwe Nokuphepha

I-FUCASO: I-Revolutionary Fully-Human BCMA CAR-T Therapy Ngokusebenza Okungaqhathanisiwe Nokuphepha
I-Optic Nerve Injury-03

I-Optic Nerve Injury-03
I-Optic Nerve Injury-02

I-Optic Nerve Injury-02
I-Optic Nerve Injury-01

I-Optic Nerve Injury-01
I-Metastatic melanoma-04

I-Metastatic melanoma-04
Umdlavuza wesibeletho-03

Umdlavuza wesibeletho-03
I-melanoma ye-ocular (ekuqaleni), ilandelwa yizimila zesibindi ze-metastatic-02

I-melanoma ye-ocular (ekuqaleni), ilandelwa yizimila zesibindi ze-metastatic-02
Isigaba esithuthukisiwe somdlavuza we-colorectal-01

Isigaba esithuthukisiwe somdlavuza we-colorectal-01
Umdlavuza we-prostate wezinga eliphezulu ohambisana nama-metastases amaningi amathambo-05

Umdlavuza we-prostate wezinga eliphezulu ohambisana nama-metastases amaningi amathambo-05
Isithombe 2.png
Isithombe 1.png
Isithombe 3.png
Isithombe 6.png
Isithombe 4.png
Isithombe 5.png
Isithombe se-WeChat_20240723170716.png
Isithombe se-WeChat_20240723170730.png
Isithombe se-WeChat_20240723170733.png
Isithombe se-WeChat_20240723170736.png
Isithombe 2.png
Isithombe 1.png
Isithombe 3.png
Isithombe 6.png
Isithombe 4.png
Isithombe 5.png
Isithombe se-WeChat_20240723170716.png
Isithombe se-WeChat_20240723170730.png
Isithombe se-WeChat_20240723170733.png
Isithombe se-WeChat_20240723170736.png

I-FUCASO: I-Revolutionary Fully-Human BCMA CAR-T Therapy Ngokusebenza Okungaqhathanisiwe Nokuphepha

I-FUCASO iyinguquko yokwelapha eqondiswe ku-BCMA eqondiswe ku-CAR-T eyenziwe yi-IASO BIO, enikeza ukusebenza kahle okungenakuqhathaniswa nokuphepha kwe-myeloma eminingi ebuyele emuva noma ephikisayo. Ngamazinga aphezulu okuphendula, ukuxolelwa okuhlala isikhathi eside, kanye nephrofayili yokuphepha eqinile, i-FUCASO inikeza ithemba elisha ezigulini futhi ibeka izinga elisha ekwelapheni kwe-CAR-T.

    Xhumana nathi
    imininingwane yomkhiqizo
    Izinzuzo ezibalulekile zeFUCASO
    Impumelelo Yomtholampilo

    Isithombe 6.png

    I-FUCASO, ethuthukiswe yi-Nanjing IASO Biotechnology, iwukwelapha okudabukisayo kwe-CAR-T okuklanyelwe ngokuqondile ukukhomba i-B-cell maturation antigen (BCMA). Lokhu kwelashwa kugqama ngenxa yokusebenza kahle komtholampilo okungenakuqhathaniswa kanye nephrofayili yokuphepha, okuhlinzeka ngethemba elisha ezigulini ezine-myeloma eminingi ebuyele emuva noma ephikisayo (r/rMM). Igunyazwe i-National Medical Products Administration (NMPA) ngoJuni 30, 2023, i-FUCASO isivele ibonise impumelelo ebalulekile ezicelweni zomtholampilo.

    Amazinga Okuphendula aphezulu: I-FUCASO iziqhayisa Ngezinga Lokuphendula Eliphelele (ORR) lama-98.9% kanye nezinga le-Complete Response (CR) elingu-82.4%, eliphakeme kakhulu kunezinye izindlela zokwelapha ezitholakalayo.

    Isithombe se-WeChat_20240723172135.png

    Ukuxolelwa Okuhlala Njalo: Iziguli ezilashwa nge-FUCASO zibonise izinga le-Progression-Free Survival (PFS) lezinyanga ezingu-12 elingu-85.5%, elibonisa ukuxolelwa kwesikhathi eside kanye nezinga lempilo elithuthukisiwe.

    Isithombe se-WeChat_20240723171917.png

    Iphrofayela Yokuphepha: Nge-≥3 grade Cytokine Release Syndrome (CRS) eyenzeka ku-1% kuphela weziguli futhi azikho izimo ezibikiwe ze-≥3 grade Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), i-FUCASO inikeza inketho yokwelashwa ephephile uma iqhathaniswa nezinye izindlela zokwelapha ze-CAR-T .

    Isithombe se-WeChat_20240723171709.jpg

    Izindleko-Ngempumelelo: Ukwelashwa kwe-FUCASO kubiza kakhulu ngaphansi kwezindlela zokwelapha ezifanayo ezitholakala e-United States, okuyenza ibe inketho esebenzayo kuhlu olubanzi lweziguli.

    Isithombe se-WeChat_20240723171801.jpg

    Ukufinyelela Umhlaba jikelele: I-IASO BIO isungule inethiwekhi yesikhungo sokwelapha esibanzi e-China, ekwazi ukusiza iziguli ezivela emhlabeni wonke ngamasevisi adidiyelwe kusukela ekubonisaneni kuya ekunakekelweni kwangemva kokwelashwa.

    Isithombe se-WeChat_20240723170716.png

    Isiguli sokuqala eselashwa nge-FUCASO sizuze iminyaka emihlanu yokuphila ngaphandle komdlavuza, okuyingqopha-mlando ephawulekayo uma kuqhathaniswa ne-Median Progression-Free Survival (PFS) yezinyanga ezingu-2.9 nje ngokunakekelwa okujwayelekile. Lokhu kugqamisa amandla e-FUCASO okuguqula isimo sokwelapha se-myeloma eminingi.

    23.jpg